Wave Life Sciences Ltd. announced a preliminary, unaudited cash and cash equivalents position of approximately $602 million as of December 31, 2025, with an expected cash runway extending into the third quarter of 2028. These results are subject to adjustment, and the company plans to report its final fourth-quarter and full-year 2025 financial results in late February 2026. The company also outlined strategic priorities for 2026, including the acceleration of development for WVE-007, an investigational INHBE GalNAc-siRNA for obesity. Initial data from a 240 mg single-dose of WVE-007 reported in 2025 showed improved body composition with fat loss similar to GLP-1 at three months, muscle preservation, and the potential for once or twice-yearly dosing. Wave expects to begin a Phase 2a multidose portion of the WVE-007 INLIGHT clinical trial in individuals with obesity in the first half of 2026, and to initiate new trials evaluating WVE-007 as an add-on to incretin therapy and as a post-incretin maintenance treatment later in the year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-009784), on January 12, 2026, and is solely responsible for the information contained therein.